Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tri Nguyen

Ophthalmology Fountain Valley, CA Medical Doctor

NPI 1669436002 CMS profile 256560

11100 Warner Ave, Suite 104, Fountain Valley, CA 92708

Open in the dashboard

General payments

$13,602

350 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tri Nguyen of Fountain Valley, CA is reported in the CMS Open Payments database as having received $13,602 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,254 46
2024 General $597 33
2023 General $933 35
2022 General $1,164 35
2021 General $1,545 87
2020 General $1,055 58
2019 General $7,055 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tri Nguyen
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Tri Nguyen were reported at $1,254. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Tri Nguyen Ophthalmology median Middle half National median
2019 $7,055 $258 $104–$655 $163
2020 $1,055 $126 $45–$321 $114
2021 $1,545 $205 $76–$534 $132
2022 $1,164 $266 $100–$678 $149
2023 $933 $308 $117–$745 $160
2024 $597 $340 $127–$846 $164
2025 $1,254 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $8,500 104 payments
  2. Allergan Inc. $1,320 77 payments
  3. Alcon Vision LLC $674 20 payments
  4. Novartis Pharmaceuticals Corporation $428 32 payments
  5. Aerie Pharmaceuticals, Inc. $390 24 payments
  6. Bausch & Lomb Americas Inc. $341 23 payments
  7. Bausch & Lomb, a division of Bausch Health US, LLC $306 8 payments
  8. Oyster Point Pharma, Inc. $297 9 payments
  9. Mallinckrodt Hospital Products Inc. $265 12 payments
  10. AbbVie, Inc. $206 7 payments
  11. Other $876 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,453 344 payments
  2. Honoraria $5,000 2 payments
  3. Travel and Lodging $1,124 3 payments
  4. Entertainment $25 1 payment
Products named General payments · program years 2019–2025
  1. Cequa $6,619 90 payments
  2. BromSite $2,327 51 payments
  3. Xelpros $615 39 payments
  4. RESTASIS MULTIDOSE $564 30 payments
  5. RESTASIS $528 31 payments
  6. XIIDRA $421 33 payments
  7. MIEBO $280 18 payments
  8. rhopressa $276 17 payments
  9. rocklatan $276 17 payments
  10. ACTHAR $265 12 payments
  11. Other $3,134 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

4,151

Median for Ophthalmology: 891

Drug cost

$1,968,594

Median for Ophthalmology: $68,233

Branded share of claims

70.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 1,021 $734,592
Cyclosporine Generic 780 $469,296
Cequa Cyclosporine Brand 564 $355,932
Vyzulta Latanoprostene Bunod Brand 125 $51,799
Combigan Brimonidine Tartrate/Timolol Brand 204 $46,903
Vevye Cyclosporine Brand 52 $46,439
Xiidra Lifitegrast Brand 36 $28,650
Bromsite Bromfenac Sodium Brand 109 $27,605
Simbrinza Brinzolamide/Brimonidine Tart Brand 116 $23,424
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 83 $17,609

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$271,202

Medicare's payments for the services billed

Medicare patients

654

Average age 77

Services billed

4,741

389 women, 265 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 56%
Arthritis 46%
Chronic kidney disease 31%
Ischemic heart disease 29%
Osteoporosis 27%
Heart failure 21%
Alzheimer's or dementia 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MIEBO
  • Bausch & Lomb Americas Inc. $145
$145 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $136
$136 564 —
LUMIGAN
  • AbbVie, Inc. $95
$95 18 —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $59
$59 — —
DURYSTA
  • AbbVie, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record